APA (7th ed.) Citation

Kristen, A., Biener, M., Hegenbart, U., Hardt, S., Schnabel, P. A., Röcken, C., . . . Giannitsis, E. (2014). Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis. International journal of cardiology, 176(3), . https://doi.org/10.1016/j.ijcard.2014.07.106

Chicago Style (17th ed.) Citation

Kristen, Arnt, Moritz Biener, Ute Hegenbart, Stefan Hardt, Philipp Albert Schnabel, Christoph Röcken, Stefan Schönland, Hugo Katus, and Evangelos Giannitsis. "Evaluation of the Clinical Use of Midregional Pro-atrial Natriuretic Peptide (MR-proANP) in Comparison to N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for Risk Stratification in Patients with Light-chain Amyloidosis." International Journal of Cardiology 176, no. 3 (2014). https://doi.org/10.1016/j.ijcard.2014.07.106.

MLA (9th ed.) Citation

Kristen, Arnt, et al. "Evaluation of the Clinical Use of Midregional Pro-atrial Natriuretic Peptide (MR-proANP) in Comparison to N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for Risk Stratification in Patients with Light-chain Amyloidosis." International Journal of Cardiology, vol. 176, no. 3, 2014, https://doi.org/10.1016/j.ijcard.2014.07.106.